Among these strategies, LLT1 plays a pivotal role, not only by shielding UCAR-T cells from allogenic NK cell-mediated rejection, but also by promoting their stemness, a critical feature that underpins durable anti-tumor efficacy, as demonstrated in both in vitro experiments and humanized models. The gene discussed is CLEC2D; the disease is neoplasm.